Alnylam's Phase 1 trial of ALN-4915 in healthy volunteers is active, not recruiting
A single ascending dose study of the siRNA candidate ALN-4915 remains active but closed to enrollment, with results due in mid-2027.
The week's filing shows one update to Alnylam Pharmaceuticals' early-stage pipeline work.
- ALN-4915, an siRNA drug, is being tested in a Phase 1, randomized, placebo-controlled, single ascending dose study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics in adult healthy volunteers.1 The study's overall status is listed as active, not recruiting, with 36 participants enrolled1 and a primary completion date estimated for July 31, 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.